While some glucose-lowering treatments are associated with weight gain (eg, sulfonylureas, thiazolidinediones and insulin), two recent classes of therapeutic agents for T2D, namely, the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), are associated with weight loss, achieved via different mechanisms: increased urinary glucose loss for SGLT2i, and promotion of satiety for GLP-1 RAs. The gene discussed is GCG; the disease is type 2 diabetes mellitus.